AstraZeneca Makes Case For Independence With $23 Bil. Pipeline Potential

The U.K. drug maker went on the offense against Pfizer’s hostile takeover attempt May 6, laying out to investors its long-term revenue guidance forecasting $45 billion in revenues by 2023. Growth will be driven by a pipeline with $23 billion in peak sales potential.